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While immunosuppressive agents are necessary to prevent the rejection of transplanted organs, and are a great
medical success story for protecting against early allograft loss, graft and patient survival over the long term are
diminished by side effects from these same drugs. One striking long-term side effect is a high rate of skin cancer
development. The skin cancers that develop in transplant recipients tend to be numerous, as well as particularly
aggressive, and are therefore a major contributor to morbidity and mortality in transplant recipients. An apparent
reason for the high incidence of skin cancer likely relates to suppression of immune surveillance mechanisms, but
other more direct effects of certain immunosuppressive drugs are also bound to contribute to cancers of UV-exposed
skin. However, over the past few years, evidence has emerged to suggest that one class of immunosuppressants,
mammalian target of rapamycin (mTOR) inhibitors, could potentially inhibit skin tumour formation through a number
of mechanisms that are still being studied intensively today. Therefore, in light of the high skin cancer incidence in
transplant recipients, it follows that clinical trials have been conducted to determine if mTOR inhibitors can significantly
reduce these post-transplant skin malignancies. Here, the problem of post-transplant skin cancer will be briefly
reviewed, along with the possible mechanisms contributing to this problem, followed by an overview of the relevant
clinical trial results using mTOR inhibitors.
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Key breakthroughs in the discovery of immunosuppressive
agents over the past three to four decades have expanded
the routine use of solid organ transplantation to the point
where demand for organs far exceed their availability.
Organ transplantation has unquestionably been a success
story brought about by medical research. In the current
state of this success, however, the transplantation commu-
nity has come to the realisation that while early organ
allograft and patient survival are excellent, long-term out-
comes have not improved substantially over the past
couple of decades. The inadequacy of organ availability
has heightened this realisation of unimproved long-term
outcomes and has caused transplant organisations to
search for reasons of explanation. There are indeed a
number of factors responsible for poor long-term results,
including chronic allograft rejection, cardiovascular disease,
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unless otherwise stated.[1,2]. Regarding the latter, it is particularly difficult to accept
the complication of post-transplant malignancies since
these recipients typically die with a well-functioning trans-
plant. Adding to the frustration is the fact that the malig-
nancies commonly occur after ten or more years post-
transplantation, meaning that the recipient is otherwise
adapting well to the allograft over the long term by not
immunologically rejecting the organ. New strategies aimed
at reducing malignancies in these patients are therefore
clearly needed.
By far the most common malignancies occurring in
transplant recipients are skin cancers. Data from the dif-
ferent registries suggest that more than half of transplant
recipients will experience at least one of a variety of skin
malignancies [3]. The predominant epithelial skin cancer
in this population is cutaneous squamous cell carcinoma
(SCC), which is characterised by lesions that subsequently
increase in frequency and multiplicity after the first lesion
is diagnosed [4,5]; the occurrence rate is increased by ap-
proximately 65–100-fold compared to the general popula-
tion [6]. Successful strategies to combat these highlyis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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significant impact on the quality of life for long-term allo-
graft recipients. Other skin tumours are also increased in
organ transplant recipients, although less frequently. Basal
cell carcinomas (BCC) are the second most common skin
tumour post-transplantation, although they do not display
a more aggressive behaviour compared to the general
population [7,8]. Interestingly, while BCC are more com-
mon (4:1) than SCC in the general population, this ratio is
completely reversed in transplant recipients, indicating
the extraordinary predilection for SCC development in
these immunosuppressed people. Highly aggressive cuta-
neous Merkel cell carcinomas are also increased 5–10-fold
in transplant recipients [9], and Kaposi’s sarcoma is dra-
matically increased to a rate up to 500-fold more than
age-matched controls [10]. Although otherwise rather
rare, Kaposi’s sarcoma accounts for approximately 6% of
all malignancies in transplant recipients. Unlike SCC
which tends to occur several years after transplantation,
Kaposi’s sarcoma occurs within the first year or two
post-transplantation and develops in close association
with human herpesvirus 8 (HHV-8) reactivation. Finally,
it should be mentioned that cutaneous malignant mel-
anoma shows only a slight increase in risk for transplant
recipients, but high mortality rates have been reported
[11,12], making it a serious concern for these patients.
A recent report indicates that cutaneous melanomas in
kidney transplant recipients show a particularly aggres-
sive tumour behaviour that is reflected in demonstrably
poor outcomes [13].
Mechanisms for increased skin cancer
While the complex topic of causes for these various
types of skin cancer cannot be comprehensively covered
in this review, a few mechanisms should be mentioned
for establishing a basic knowledge. The most obvious
factor thought to affect cancer development in trans-
plant recipients is systemic suppression of the immune
system caused by anti-rejection drugs. There are two pri-
mary consequences of immune suppression, one being the
inhibition of immune reactions capable of recognizing and
destroying tumour cells [14] and the other being the per-
missiveness of viral infections that are associated with
common skin cancers (e.g. HHV-8, Kaposi’s sarcoma;
human papillomavirus, SCC; Merkel cell polyomavirus,
Merkel cell carcinoma) [15]. However, it is becoming in-
creasingly clear that non-immunological factors are also
important, such as direct effects of certain immunosup-
pressive drugs on neoplasms. For example, cyclosporine
(calcineurin inhibition) is known to promote tumour cell
invasiveness [16] and boost vascular endothelial growth
factor-induced angiogenesis that nourishes cancer growth
[17]. Importantly, cyclosporine is also known to have an
inhibitory effect on DNA repair mechanisms [18], whichare understandably critical for the repair of damage caused
by UV light on exposed areas of the skin. Similarly, an-
other immunosuppressant, azathioprine, is well known
to be mutagenic, acting synergistically with UV radi-
ation damage in promoting skin cancer pathogenesis
[19-21]. Therefore, commonly used immunosuppres-
sants in transplant recipients demonstrate activities that
are likely to promote the development of skin tumours.
Indeed, several experimental animal studies support this
theory, in that treatment with daily immunosuppressive
doses of cyclosporine causes tumours to grow at a faster
rate [17,22,23].
Potential for mTOR inhibition to reduce skin
cancer
There has been much debate, testing and intensive con-
tinuing research regarding the potential anti-tumour
effects of mammalian target of rapamycin (mTOR) in-
hibitors [24-26]. Inhibition of mTOR sets up a unique
molecular scenario whereby it is plausible that various
aspects of tumour development could be inhibited while
at the same time causing a general immunosuppression
that protects allografts from rejection. The mTOR path-
way is essential for cell growth and proliferation and
influences processes such as autophagy, serving as a
pivotal regulatory point for the coordination of cell sig-
nalling with nutrient availability [27,28]. Interestingly,
both cells of the immune system and of tumour entities
require this type of coordination and therefore are influ-
enced by inhibition of mTOR. Although this concise re-
view does not allow space for going into details about
the intricacies of the two different mTOR complexes, it
should be mentioned here that the mTOR inhibitors
used for immunosuppression in transplant recipients
(sirolimus and everolimus) primarily inhibit mTOR
complex 1 [29,30], and this is where the discussion will
focus; subsequently in this review, when referring to
mTOR inhibition, it is generally in reference to inhib-
ition of mTOR complex 1.
In the case of the immune system, a primary effect of
mTOR inhibition is through blocking of the IL-2 prolif-
eration signal to T cells, which is necessary to expand T
cell responses directed specifically against the alloanti-
gens expressed by the transplanted organ; thus, mTOR
inhibition is highly immunosuppressive. It should also
be mentioned however that mTOR inhibition has other
effects on specific populations of immune cells, includ-
ing inhibition of antigen-presenting cell maturation [31]
and promotion of T regulatory cell development [32].
The complex effects of mTOR inhibition on the immune
system have been reviewed elsewhere [33], but it can be
summarised here that there are both inhibitory and potent
stimulatory effects on immune cell populations that are
likely mediated by mTOR inhibitors. Therefore, while
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that mTOR inhibitors have widely different effects on
immune cells, making it difficult to predict what the
overall effect may be on tumour formation; indeed, the
effect may vary from one tumour type to the other, de-
pending on their immunogenicity.
Nonetheless, there is a large body of literature that in-
dicates that mTOR inhibitors may be effective against
various aspects of tumour development. Indeed, there
are several possible mechanisms of action that have been
described. While this is not meant to be a full review of
anti-tumour mechanisms potentially involved, it is worth
pointing out some of the key roles of the mTOR pathway
that could impact skin cancer development. For instance,
angiogenesis relies on vascular endothelial growth factor
expression and signalling in supportive tumour vessel
structures, which are dependent on the mTOR pathway
[34]. We have shown that mTOR inhibitors dramatically
block tumour angiogenesis, which leads to substantially
reduced tumour growth in animal models [17]. Another
aspect is the multitude of mutations in key signalling mol-
ecules that have been described upstream of the mTOR
complex 1 signalling node that result in constitutive acti-
vation of the mTOR pathway and thus uncontrolled cell
growth and proliferation; included in this extensive list are
mutations in PTEN, TSC1/2 and Ras/Raf that lead to
mTOR complex 1 activation [24]. Pkd-1 mutations can
also result in triggering of the mTOR pathway and have
been linked to cell proliferation and the development of
polycystic kidney disease; blocking mTOR with rapamycin
can substantially inhibit the proliferation of cysts in mice
with this conditionally expressed mutation [35]. Therefore,
inhibition of mTOR has substantial mechanistic potential
to be considered overall as an anti-cancer agent.
Particularly relevant for the topic of skin cancers in
transplant recipients may be the recently discovered po-
tential anti-viral effects of mTOR inhibitors [36,37]. The
close association of viral infection (as discussed earlier)
with the development of different skin malignancies
brings this property into focus. While the mechanismsTable 1 Randomised multicentre clinical trials with skin cance
Study Patient number Primary endpoint Pri
Australian study Control: 47 (23)a Number of new NMSC/patient/year Sig
mTORi: 39 (19)
TUMORAPA Control: 56 (12) Survival free of new SCC Sig
mTORi: 64 (22)
RESCUE Control: 81 (14) Risk of new SCC No
mTORi: 74 (39)
SCC squamous cell carcinoma, BCC basal cell carcinoma, NMSC non-melanoma skin
group, HR hazard ratio.
aNumber in parentheses represents patients dropping out of study. For the definitio
the protocol, see the individual publications.for the anti-viral effect are not well understood yet, it
seems some viruses are responsive to mTOR inhibition
[37], and mTOR inhibitors have been shown to boost
CD8 T cell responses induced by viral vaccines, even at
immunosuppressive doses in non-human primates [38].
Therefore, if the anti-viral effects of mTOR inhibitors
are better characterised and eventually confirmed, this
may be another important mechanism to consider in the
fight against post-transplant skin malignancies.
Key skin cancer trials in transplant recipients
Apart from the experimental and theoretical view towards
reducing skin cancer in organ transplant recipients with
mTOR inhibitors, the first clinical trials with this aim have
now been published. In this part of the review, results
from the key trials will be discussed (see Table 1).
Australian skin cancer trial
The first report of a randomised, multicentre clinical
trial tested the effects of switching from calcineurin
inhibitor-based immunosuppression to sirolimus on the
risk for development of non-melanoma skin cancer
(NMSC) in renal transplant recipients [39]. A total of 87
transplant patients at a high risk for NMSC were rando-
mised at least 1 year after transplantation to continue on
a calcineurin inhibitor-based immunosuppression or be
switched to sirolimus; the primary endpoint was number
of biopsy-confirmed new NMSC per patient per year.
Over a 2-year observation period, SCC occurred at a sig-
nificantly lower rate in the sirolimus group of patients,
although the rate of basal cell carcinomas was the same.
Also, a lower rate of new NMSC developed in the
sirolimus-converted group. Furthermore, it took more
than twofold the number of days for a new NMSC to
occur in the sirolimus versus control group of patients.
Importantly, the conversion to sirolimus did not result
in an increased risk for having an acute kidney rejection
episode, but there was a high rate of treatment discon-
tinuation in the sirolimus group (42.6%) due to typical
well-known side effects associated with mTOR inhibitorr as the primary endpoint
mary endpoint result Comments
nificant A significant decrease in SCC, but not BCC
nificant patients with 1 prior SCC benefited significantly;
those with multiple previous SCC did not
significantly benefit
t significant HR improved in 1-year analysis, but did not after
2-year follow-up
cancer, Control patients not receiving mTOR inhibitors, mTORi mTOR inhibitor
n of a dropout and number of patients that completed the study according to
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to mTOR inhibitor did have a positive clinically signifi-
cant effect on skin cancer development in this study.
TUMORAPA
Within a couple of months after the release of the
Australian trial results, Euvrard and colleagues published
data from a similar clinical trial that focussed on SCC in
kidney transplant recipients [40]. This trial used a combin-
ation of data from two registered trials, TUMORAPA-1
and TUMORAPA-N, which aimed to enrol patients with
a first SCC and after multiple SCC post-transplantation,
respectively. A total of 120 patients were enrolled in this
combined study, which was a calcineurin inhibitor to siro-
limus conversion protocol looking at SCC-free survival
2 years after randomisation. The rate of SCC-free survival
was significantly longer with sirolimus conversion, where
22% of patients developed new SCC compared to 39% in
the group maintained on calcineurin inhibitors. An im-
portant observation in this study was that significance in
the mTOR inhibitor effect held in the group of patients
that had only a single pre-randomisation SCC, but was
lost when recipients had multiple SCC prior to entry into
the study; it should be added however that the study may
not have been adequately powered to see such a differ-
ence. Another potentially important observation was that
patients did experience significant side effects causing
treatment discontinuation in the sirolimus conversion
group, but these side effects were substantially fewer when
a slower conversion (over >7 days) was performed. The
Australian and TUMORAPA trials in large part reached a
similar conclusion that mTOR inhibitors inhibit skin can-
cer in high-risk kidney transplant recipients.
RESCUE
Another related clinical trial in the Netherlands and the
United Kingdom was performed during approximately
the same time frame as the previously cited trials and is
referred to as the RESCUE trial [41]. Similar to the first
two trials discussed, RESCUE was a randomised, multi-
centre study with a 2-year follow-up in kidney transplant
recipients that had experienced at least one pre-
randomisation SCC. A total of 155 patients were rando-
mised into a group maintained on their non-mTOR
inhibitor-based regime or into an arm where conversion
to sirolimus was performed. The primary endpoint was
met when the patient developed a new SCC within the
2-year observation period. Results from this trial are in-
teresting to contrast with the other two trials, since no
significant decrease in new SCC (the primary endpoint)
was observed in the sirolimus group as a whole after
2 years, but additional analyses revealed that there was a
significant 50% decrease in risk (measured by hazard ra-
tio) after only 1 year of observation. A provocativeconclusion to this finding is that mTOR inhibitors delay,
but do not prevent, skin cancers in these patients; a
longer-term follow-up would be necessary to begin to ad-
dress this issue. An additional finding in this study was a
substantial improvement in hazard ratio for those patients
that entered the trial with only one previous SCC, which
is consistent with the results from TUMORAPA. As with
the other trials, a high discontinuation rate (39%) was ob-
served in the sirolimus group due to adverse side effects.
Additional useful trial results
It should be mentioned that other trials have investi-
gated the effect of mTOR inhibitors on development of
skin cancer in transplant recipients, including a small
randomised single-centre German study published by
Salgo and colleagues [42]. This trial showed also that sir-
olimus conversion in renal transplant recipients has an
inhibitory effect on development of NMSC, where only
1/16 sirolimus-converted versus 8/17 control group pa-
tients developed skin cancer. Results from large siroli-
mus conversion trials, where de novo malignancies were
examined only as secondary endpoints, also show a bene-
ficial effect in terms of skin cancer occurrence [43,44]. Evi-
dence is emerging to show that everolimus is also likely to
have a similar inhibitory effect on skin cancer in trans-
plant recipients [45,46]. Finally, it is important to point
out the success reported in the treatment of Kaposi’s sar-
coma with mTOR inhibitor conversion in transplant re-
cipients. Several key studies have shown a dramatic effect
of mTOR inhibitor conversion on lesion stabilisation, re-
duction and even disappearance [47-49]. Kaposi’s sarcoma
is potentially a good target for mTOR inhibitors, since
they are highly vascular tumours and linked directly with
HHV-8 viral infection.
Conclusions
Skin cancer is a substantial problem in organ transplant
recipients that is attributed to the immunosuppressive
drugs that are most commonly used to prevent allograft
rejection. In particular, evidence suggests that the cal-
cineurin inhibitors and azathioprine contribute to the
development of skin neoplasms both through paralysis
of immune surveillance and by promotion of tumour
vascularisation, cancer cell invasiveness and exacerba-
tion of DNA damage or inhibition of DNA repair. While
suppression of the immune reactivity against cancer
cannot be completely avoided with an immunosuppressive
drug, mTOR inhibitors have a unique potential to both
suppress an immune response to the organ allograft and
promote mechanisms that can potentially inhibit tumour
development. The basic research to better understand this
phenomenon continues to evolve at a steady pace, but
in the meantime, clinical trials in transplant recipients
already indicate that skin cancer can be reduced by
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itors. Results from clinical studies suggest also that pa-
tients at a high risk for skin cancer receive the greatest
benefit when mTOR inhibitors are used early, before
multiple lesions have already developed. The key to taking
advantage of this benefit will be the institution of im-
proved protocols that minimise the adverse side effects of
mTOR inhibitor use in transplant recipients that undergo
immunosuppression switching. Therefore, mTOR inhibi-
tors could be a “game changer” to reduce the problem
of post-transplantation skin cancer, but more research
will be necessary to optimise clinical protocols that will
be widely acceptable for high-risk patients that can
benefit from this general strategy.
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